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The incidence of dog rabies in Limpopo Province, 
South Africa, increased from 5 cases in 2004 to 100 in 
2006. Human rabies had last been conﬁ  rmed in 1981, but 
investigations instituted after an index case was recognized 
in February 2006 identiﬁ  ed 21 conﬁ  rmed, 4 probable, and 
5 possible human cases between August 5, 2005, and De-
cember 31, 2006. Twelve of these case-patients were iden-
tiﬁ  ed retrospectively because the diagnosis of rabies was 
not considered: 6 of these patients consulted a traditional 
healer, 6 had atypical manifestations with prominent ab-
dominal symptoms, and 6 of 7 patients tested had elevated 
liver enzyme activity. Molecular genetic analysis indicated 
that outbreak virus strains were most closely related to 
recent canine strains from southern Zimbabwe. Delayed 
recognition of the human cases may have resulted from 
decreased clinical suspicion after many years of effective 
control of the disease and the occurrence of atypical clinical 
presentations.
D
espite the availability of effective human and animal 
vaccines against rabies, and other measures for its 
control, rabies continues to account for at least 55,000 hu-
man deaths each year, mainly in the developing countries 
of Africa and Asia (1,2). In these countries, most human 
rabies infections result from exposure to infected dogs, by 
bites, scratches, and mucosal exposures (3). Rabies vacci-
nation of animals and postexposure prophylaxis (PEP) for 
humans is prohibitively expensive for most African gov-
ernments, and it has long been contended that the effects of 
rabies are underestimated in Africa (4).
Typical furious rabies occurs as an encephalitis, often 
with characteristic features such as hydrophobia and saliva-
tion, following a brief, nonspeciﬁ  c, febrile prodrome. Less 
commonly, rabies may occur in the paralytic form in which 
characteristic clinical features may be absent (3,5).
Limpopo is the northernmost province in South Af-
rica and shares borders with Zimbabwe and Botswana. To 
the East, Limpopo is ﬂ  anked by the Kruger National Park 
and Mozambique (Figure 1). The climate is variable with 
temperate and subtropical areas, and most of the popula-
tion live in rural villages and subsist by farming maize and 
livestock.
Since the 1970s, most human rabies cases in South Af-
rica have occurred in KwaZulu-Natal Province, where the 
major animal vector is the domestic dog (6). Human rabies 
is much less common in areas such as Limpopo Province, 
where the major animal vectors are wild animals such as 
the black-backed jackal species (Canis mesomelas), be-
cause these animals are less likely to come into contact 
with humans. Before this report, the most recent 2 labora-
tory-conﬁ  rmed human rabies cases in Limpopo Province 
occurred in 1980 and 1981 (R. Swanepoel, pers. comm.). 
We describe the epidemiologic, clinical, and viral molecu-
lar features of an outbreak of rabies in Limpopo Province, 
South Africa, in 2005–2006.
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Methods
Animal Rabies Surveillance
Brain specimens from all animals with suspected ra-
bies in South Africa were submitted to the Rabies Refer-
ence Laboratory at Onderstepoort Veterinary Institute, 
Pretoria. Routine data collected included species, location 
of case-patient, and date of specimen collection. Archived 
data on conﬁ  rmed animal rabies cases from Limpopo since 
January 1994 were reviewed. An animal case was deﬁ  ned 
as any case that was laboratory conﬁ  rmed by ﬂ  uorescent 
antibody test (FAT) (7) or virus isolation after specimen 
inoculation into suckling mice and monitoring for signs of 
rabies infection over 28 days.
Dog vaccine coverage was estimated as the number of 
doses of vaccine administered to dogs per year divided by 
the estimated dog population. A ratio of 7 persons to 1 dog 
was used to estimate the dog population based on unpub-
lished survey data (E. Dyason, pers. comm.). Estimates of 
the human population by district were supplied by Statis-
tics South Africa (Stats SA, Pretoria, South Africa).
Human Rabies Surveillance
Human rabies is notiﬁ  able in South Africa (Health Act 
No. 63, 1977); diagnostic specimens from suspected case-
patients were submitted to the Special Pathogens Unit at 
the National Institute for Communicable Diseases, Johan-
nesburg. The diagnosis of rabies was conﬁ  rmed by using 
FAT on brain tissue (7); by using a heminested reverse 
transcriptase–PCR (RT-PCR) of saliva (8); or by isolat-
ing virus from brain, saliva, and cerebrospinal ﬂ  uid (CSF) 
specimens as described above. Serum and CSF specimens 
received were tested for antirabies antibodies, and CSF 
specimens were tested for viral RNA by RT-PCR. Sero-
logic testing was performed by using indirect immunoﬂ  uo-
rescence (9).
Epidemiologic Investigation of Human Cases
The study team visited hospitals in the outbreak area in 
February 2006. Potential cases of rabies (meeting the clini-
cal case deﬁ  nition) in the previous 12 months were identi-
ﬁ  ed by clinician interviews, and prospective active surveil-
lance was introduced for new suspected rabies cases.
Data were collected on a standardized data collection 
form and included demographic data, clinical and laborato-
ry features, history of animal exposure, management of the 
initial bite exposure, and patient outcomes (Table). Data 
were obtained by review of clinical records and interview 
of attending clinicians. For 3 probable cases, no clinical 
records or laboratory results were available, and data were 
obtained only by interview of the attending clinician. Data 
on the cost and numbers of doses of vaccine and immu-
noglobulin distributed in Limpopo Province were obtained 
from relevant manufacturers.
Case Deﬁ  nitions
Clinical case. A clinical case-patient was deﬁ  ned as 
any person who died after January 1, 2005, and who re-
sided in Limpopo Province before onset of illness with 1 of 
the following clinical symptoms—delirium, hydrophobia, 
salivation, acute psychosis, acute ﬂ  accid paralysis, muscle 
spasms, convulsion or respiratory paralysis—and with no 
other identiﬁ  ed cause of death.
Possible case. A possible case-patient was deﬁ  ned as a 
person who met the clinical case deﬁ  nition, but whose case 
was not laboratory conﬁ  rmed, and who had no documented 
history of animal exposure.
Probable case. A probable case-patient was deﬁ  ned as 
a person who met the clinical case deﬁ  nition, but whose 
case was not laboratory conﬁ  rmed, and who had history of 
exposure to a suspected rabid animal.
Conﬁ  rmed case. A conﬁ  rmed case-patient was deﬁ  ned 
as a person who met the clinical case deﬁ  nition and had 
laboratory-conﬁ  rmed rabies.
Molecular Analysis of Viruses Obtained 
from Animal and Human Rabies Case-Patients
After viral RNA underwent extraction and RT-PCR 
(10,11), the amplicons obtained were puriﬁ  ed with a com-
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Figure 1. Provinces of South Africa, and neighboring countries. 
Inset shows a choropleth map of the number of conﬁ  rmed  dog 
rabies cases by district in Limpopo Province in 2005–2006 and the 
location of human cases (4 case-patients, for whom coordinates of 
place of residence were unavailable, were excluded).Reemerging Rabies, South Africa
mercial kit (Wizard SV Gel and PCR Clean-Up System, 
Promega, Madison, WI, USA) and sequenced bidirection-
ally on an ABI377 automated DNA sequencer (Applied 
Biosystems, Foster City, CA, USA) with the G/L primer 
set. A 592-bp nucleotide portion of the cytoplasmic domain 
of the glycoprotein and the G-L intergenic region of the 
virus isolates included in the study sample were aligned in 
ClustalW (12). A phylogenetic tree was constructed with 
the neighbor-joining method (13) in MEGA (Molecular 
Evolutionary Genetics Analysis) software version 2.1 (14), 
and 1,000 replications. The phylogenetic tree was visual-
ized with TreeView (15).
All available isolates from humans and a panel of dog 
rabies virus isolates from Vhembe were selected (online Ap-
pendix Table, available from www.cdc.gov/EID/content/
13/12/1879-appT.htm). Virus isolates from other prov-
inces in South Africa and neighboring countries were also 
included in phylogenetic reconstruction of the molecular 
epidemiology. 
Results
Animal Rabies Cases
From 1994 through 2004, 8 to 76 laboratory-conﬁ  rmed 
animal rabies cases were identiﬁ  ed from Limpopo Province 
annually. Most of these cases were in C. mesomelas (black-
backed jackal) and in livestock (mainly cattle) (Figure 2). 
C. mesomelas case numbers increased to 12 in 2005 and 
16 in 2006.
Fewer than 10 rabies cases per year were reported from 
Limpopo in domestic dogs (Canis familiaris) from 1994 
through 2004 (Figure 2). The number of laboratory-con-
ﬁ  rmed dog rabies cases increased markedly from 5 in 2004 
to 35 in 2005 and 100 in 2006 (Figure 3). Most dog cases 
(106/135, 79%) in 2005 and 2006 came from the Vhembe 
District. The mean estimated dog vaccination coverage in 
Vhembe District from 1997 through 2005 was 39%; annual 
coverage estimates ﬂ  uctuated but ranged from 4% to 60% 
(E. Dyason, pers. comm.).
Human Rabies Cases
Detection of the Outbreak
Rabies was conﬁ  rmed by RT-PCR testing on a saliva 
specimen from the index case-patient, a 10-year-old boy 
who was brought to the hospital on February 7, 2006 (Fig-
ure 3). Twelve patients with encephalitis that met the case 
deﬁ  nition were identiﬁ  ed retrospectively, and rabies was 
conﬁ  rmed by IFA for 2 of these patients for which brain 
tissue was available and by RT-PCR of saliva for a further 
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Table. Clinical and laboratory features of confirmed, probable, and possible human rabies cases, Limpopo Province, South Africa,
2005–2006
Characteristic
No. confirmed 
cases/total (%) 
No. probable 
cases/total (%) 
No. possible 
cases/total (%)  Total 
Clinical features 
  Hypersalivation  19/21 (90)  4/4 (100)  1/2 (50)  24/27 (88) 
  Agitation  14/21 (67)  2/4 (50)  0/2 (0)  16/27 (59) 
  Weakness or paralysis  14/21 (67)  3/4 (75)  2/2 (100)  19/27 (70) 
  Fever  14/21 (67)  1/4 (25)  1/2 (50)  16/27 (59) 
  Hallucinations  11/21 (52)  4/4 (100)  1/2 (50)  16/27 (59) 
  Confusion  12/21 (57)  0/4 (0)  1/2 (50)  13/27 (48) 
  Hydrophobia  8/21 (38)  1/4 (25)  0/2 (0)  9/27 (33) 
  Alternating lucidity and confusion  8/21 (38)  0/4 (0)  1/2 (50)  9/27 (33) 
  Aggression  6/21 (29)  1/4 (25)  0/2 (0)  7/27 (26) 
  Vomiting  6/21 (29)  1/4 (25)  1/2 (50)  8/27 (30) 
  Spasms  5/21 (24)  0/4 (0)  0/2 (0)  5/27 (19) 
  Convulsions  5/21 (24)  0/4 (0)  1/2 (50)  6/27 (22) 
  Abdominal distension  4/21 (19)  1/4 (25)  0/2 (0)  5/27 (19) 
  Pain at the bite site  4/21 (19)  0/4 (0)  1/2 (50)  5/27 (19) 
  Diarrhea  2/21 (10)  1/4 (25)  0/2 (0)  3/27 (11) 
  Insomnia  2/21 (10)  1/4 (25)  0/2 (0)  3/27 (11) 
Laboratory results 
  Elevated leukocyte count (>10 x 10
9 cells/L)  9/19 (47)  4/4 (100)  0/2 (0)  13/25 (50) 
  Elevated urea (>7 mmol/L)  11/19 (61)  2/4 (50)  0/2 (0)  13/25 (50) 
 Elevated  creatinine  (>100  μmol/L) 1/19 (5)  1/4 (25)  0/2 (0)  2/25 (1) 
  Elevated total bilirubin (>21 μmol/L)  0/5 (0)  0/4 (0)  0/1 (0)  0/10 (0) 
  Elevated conjugated bilirubin (>6 μmol/L) 0/5 (0)  0/4 (0)  0/1 (0)  0/10 (0) 
  Elevated alkaline phosphatase (>120 IU/L)  3/5 (60)  3/4 (75)  1/1 (100)  7/10 (70) 
  Elevated gamma glucosyl transferase (>35 IU/L)  2/5 (40)  0/4 (0)  0/1 (0)  2/10 (20) 
  Elevated alanine transaminase (>40 IU/L)  1/5 (20)  2/4 (50)  0/1 (0)  3/10 (30) 
  Elevated aspartate transaminase (>40 IU/L)  2/5 (40)  2/4 (50)  0/1 (0)  4/10 (40) RESEARCH
2 patients. The earliest identiﬁ  ed case-patient was a 9-year-
old boy who was admitted in August 2005 with a history of 
dog bite. An admission CSF specimen, submitted for rabies 
diagnosis, was found to be negative by both RT-PCR and 
antibody testing.
Description of the Outbreak
From January 1, 2005, through December 31, 2006, 
21 conﬁ  rmed, 4 probable, and 5 possible human rabies 
cases were identiﬁ   ed (Figure 3). The earliest identiﬁ  ed 
case-patient became ill on August 5, 2005. The numbers 
of conﬁ  rmed cases peaked in March 2006. Case numbers 
decreased from May 2006, but 1 to 2 cases per month con-
tinued to be reported until December 31. Of the 30 case-pa-
tients, 28 were from the Vhembe District (Figure 1).
Twenty-seven cases were in children 3–12 years of age 
(median 9 years). All case-patients were hospitalized. The 
median duration from admission to death was 4 days (range 
1–25 days). All 4 patients who survived >10 days were ad-
mitted to intensive care units.
Clinical and Laboratory Features of Human Cases
The median incubation period was 8 weeks (range 
3–28 weeks) for the 22 case-patients for whom the date of 
exposure was known. The most common clinical feature 
observed in patients with conﬁ  rmed cases was salivation 
(19/21, 90%), followed by agitation (14/21, 67%), weak-
ness (14/21, 67%), fever (14/21, 67%), and hallucinations 
(11/21, 52%) (Table).
The median period between when a person ﬁ  rst expe-
rienced illness and when the person sought healthcare was 
2 days (range 0–8 days) in the 19 patients for whom date 
of onset of symptoms was available. Lumbar puncture was 
performed on 14 patients. CSF ﬁ  ndings were within nor-
mal limits for all 11 patients who did not have blood in 
the CSF specimen. Nine of 19 patients tested (47%) had an 
elevated leukocyte count (>10 ×109/L), and 11 (61%) of 18 
had elevated urea levels (>7 mmol/L). All 4 patients tested 
for HIV were HIV seronegative. No abnormalities were de-
tected in hemoglobin level, platelet count, or erythrocyte 
sedimentation rate in any of the 19 patients.
The cluster of 11 case-patients who sought treatment 
before the index case-patient was identiﬁ  ed (excluding the 
primary case-patient in whom rabies was suspected) was 
reviewed separately to identify possible reasons for the de-
layed diagnosis of rabies. Of these patients, 6 reported hav-
ing consulted a traditional healer before visiting the clinic. 
Clinical and laboratory data were available for 8 patients: 
6 exhibited prominent abdominal symptoms (including ab-
dominal distension in 4, vomiting in 3, and diarrhea in 2), 
3 of whom reported consulting a traditional healer. Liver 
function tests were performed for 7 case-patients; of these, 
6 had elevated alkaline phosphatase enzyme levels (>120 
IU/L). Clinicians’ differential diagnoses of these cases in-
cluded viral encephalitis, typhoid, pyrexia of unknown ori-
gin, epilepsy, panic attacks, poisoning or toxin exposure, 
and Guillain-Barré syndrome. Five patients were not asked 
about possible animal exposures.
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Figure 2. Laboratory-conﬁ   rmed animal rabies cases, Limpopo 
Province, South Africa, 1994–2006.
Figure 3. Numbers of 
possible, probable, and 
conﬁ   rmed human cases 
and laboratory-conﬁ  rmed 
domestic dog rabies cases 
by month of diagnosis, 
Limpopo Province, South 
Africa, 2005–2006. Reemerging Rabies, South Africa
For 7 case-patients reported in this outbreak, speci-
mens were not submitted for rabies diagnosis. For all 21 
conﬁ  rmed case-patients, saliva specimens were positive by 
RT-PCR; for 7 of these case-patients, brain tissue speci-
mens sampled on postmortem examination were also posi-
tive by IFA, and for 3 unvaccinated patients, serum speci-
mens were positive for rabies antibodies. Virus isolation 
was attempted on 7 saliva specimens and was successful 
for 5. No virus isolation was attempted on brain specimens 
because all were received in formalin, despite guidelines 
for submission of samples in glycerol saline. All 7 CSF 
specimens were collected during the ﬁ  rst week of illness 
and were negative for antirabies antibodies and by RT-
PCR. A saliva specimen from 1 patient with typical rabies 
symptoms, who had been bitten by a dog with suspected 
rabies, tested negative by RT-PCR. He was classiﬁ  ed as a 
probable case-patient; postmortem brain tissue could not 
be obtained.
Management of Exposures
All 24 case-patients who were asked about a history of 
animal exposure reported an exposure to a potentially rabid 
dog. All documented exposures were category 3 (high-risk) 
exposures, i.e., a bite or scratch that drew blood or a lick to 
mucous membranes or broken skin. Most patients (20/24, 
83%) reported a bite, but 3 patients reported scratches only, 
and 1 reported that the dog had licked and nibbled at mu-
cous membranes. For 22 case-patients with a known date 
of exposure, 15 (68%) exposures had occurred before the 
outbreak was identiﬁ  ed and control measures were imple-
mented.
Of 16 case-patients for whom site of exposure was re-
ported, half of the exposures (8) were on the lower limb, 
but exposures were also reported to the upper limb (3), 
trunk (2), and head and neck (3). Most exposures were to 
unknown dogs, but 5 of 20 case-patients reported exposure 
to their own dog. Of the 18 case-patients able to give a 
history of the management of the original bite exposure, 
12 (67%) did not report to a clinic at the time of exposure. 
All 6 case-patients who sought treatment at clinics received 
wound cleaning, but only 2 were vaccinated (1 received 
only 1 dose).
One case-patient, a 4-year-old boy who had been bit-
ten on the left cheek by a dog on September 6, 2006, re-
ceived antirabies immunoglobulin (Rabigam, National 
Bioproducts Institute, Pinetown, South Africa) in addition 
to vaccination with Verorab (Sanoﬁ   Pasteur, Lyon, France) 
within 12 hours of exposure. Details of wound cleaning are 
unclear, although the wound was not sutured. The patient 
received antirabies immunoglobulin at the recommended 
dose of 20 IU/kg, half injected into the wound site and 
half injected into the deltoid muscle, and rabies vaccine 
administered into the deltoid muscle on days 0, 3, 7, and 
14. Whether this was the deltoid opposite to that used for 
the immunoglobulin was not known. Rabies developed in 
the patient on September 23, 2006 (17 days after exposure) 
and was conﬁ  rmed by RT-PCR of brain tissue; the patient 
died on September 25, 2006. Vaccine and immunoglobu-
lin batches were found to meet required potency standards 
(Z. Goondiwala, Sanoﬁ   Pasteur, pers. comm.; C. Rochat, 
National Bioproducts Institute, pers. comm.).
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Figure 4. Neighbor-joining tree of canid rabies viruses from humans 
and animals from Limpopo (LP), Mpumalanga (MP), North West 
(NW), Free State (FS), Eastern Cape (EC), Northern Cape (NC), 
KwaZulu-Natal (KZN), and Western Cape (WC) Provinces of South 
Africa (SA) and neighboring countries of Zimbabwe, Mozambique, 
and Namibia. The Pasteur virus strain (PV) was used as the 
reference strain in the sequence alignment. Horizontal scales 
represent the evolutionary distance; vertical lines are for clariﬁ  cation 
purposes only. The scale bar indicates nucleotide substitutions per 
site. Viruses are identiﬁ  ed by a laboratory reference number, source 
animal, locality of origin, and year of isolation. A–F represent virus 
lineages supported by bootstrap values of >70%; sublineages are 
indicated numerically. *Identical strains.RESEARCH
Molecular Epidemiology
Phylogenetic analysis of nucleotide sequences indicat-
ed that the viruses originating from humans in the Vhembe 
area of Limpopo were genetically indistinguishable from 
those obtained from domestic dogs in the same geographic 
area (Figure 4). Notably, this cluster represented a new 
phylogenetic group not previously encountered in Limpopo 
Province (16) and clearly distinct from the viruses isolated 
from C. mesomelas from Limpopo. Outbreak viruses were 
most closely related to viruses obtained from dogs and jack-
als across the border in southern Zimbabwe (sublineage 
A1). A second closely related sublineage (A2) was com-
posed of viruses from southeastern Zimbabwe and western 
Mozambique, which suggests that a dog rabies cycle exists 
within South Africa, Zimbabwe, and Mozambique. The 
inclusion and analysis of rabies virus isolates from other 
provinces of South Africa and neighboring countries did 
not suggest any close link with the outbreak viruses.
Control Measures
Central-point dog vaccination campaigns in villages in 
the affected area were intensiﬁ  ed after identiﬁ  cation of the 
increased numbers of rabies cases in domestic dogs. A com-
munity awareness program related to the hazards of dog bites 
and the importance of timely visits to the clinic for rabies 
postexposure prophylaxis was established in February 2006. 
Furthermore, healthcare workers were educated regarding 
appropriate management of dog bites. Vaccine and immuno-
globulin availability was improved by increasing the number 
of facilities providing the vaccine and by ensuring that pa-
tients did not have to pay for treatment. Registers of dog bite 
cases were implemented in clinics that did not have existing 
registers in March 2006. All registering staff emphasized the 
importance of documentation and follow-up for those not re-
turning for all scheduled doses of rabies vaccine.
The combined number of doses of human rabies vac-
cine (human diploid cell [Mérieux Inactivated Rabies Vac-
cine, Aventis Sanoﬁ   , Lyon, France], puriﬁ   ed Vero cell 
vaccine [Verorab, Aventis Pasteur], and inactivated chick 
embryo vaccine [Rabipor, Biovac, Johannesburg, South 
Africa]) used in Limpopo Province in the public sector in-
creased from 3,000 in 2004 to 6,000 in 2005 and 56,000 in 
2006 (R. Watson, Biovac, pers. comm.). Use of antirabies 
immunoglobulin (Rabigam, National Bioproducts Insti-
tute, Pinetown, South Africa) also increased over the same 
period with ≈100 doses given in 2004, increasing to 500 in 
2005 and 2,500 in 2006 (C. Rochat, National Bioproducts 
Institute, pers. comm.). At a cost of 130 South African rand 
(R130; US $18) per vaccine dose and R300 (US $43) per 
immunoglobulin dose, total cost for biologics alone is esti-
mated at 8 million R (≈US $1.1 million) for the year 2006. 
This ﬁ  gure would be substantially higher with the inclusion 
of patient costs and other indirect costs.
Discussion
We describe an outbreak of human rabies in a prov-
ince of South Africa where rabies had been well controlled 
for >10 years. Late recognition of this outbreak resulted in 
delayed implementation of control measures. Although the 
clinical features of classic rabies have been described as 
unmistakable (5), the diagnosis may be missed due to low 
index of suspicion and variable clinical features (17), as oc-
curred in this outbreak. Cases of rabies may be incorrectly 
attributed to other causes of pyrexia and confusion com-
mon to rural Africa, including cerebral malaria, bacterial 
infections, and infection with HIV (18,19).
In this outbreak, the clinical signs and symptoms of 
the initial case-patients may have been altered due to use 
of traditional medicines. Of 12 case-patients in whom the 
diagnosis of rabies was missed, 6 reported having visited 
a traditional healer before seeking treatment at a hospital. 
The use of traditional medicines is common in rural set-
tings in South Africa (20,21) and may result in toxicities, 
including abdominal and psychiatric symptoms and abnor-
mal liver function test results (22). These medicines could 
have contributed to the atypical manifestations in some 
cases. In addition, clinicians may have attributed some of 
the neurologic symptoms to herbal intoxication.
Nevertheless, rabies was in fact suspected in the pri-
mary case-patient, identiﬁ  ed in August 2005. The diagno-
sis was not, however, conﬁ  rmed because an inappropriate 
specimen (a CSF specimen taken on admission) was sub-
mitted. Anti-rabies antibodies in the CSF are not usually 
detected <1 week after the onset of clinical illness, and RT-
PCR results for rabies RNA on CSF may be negative in ra-
bies cases; thus, a negative CSF result does not exclude the 
diagnosis of rabies (17,18,23). It is therefore recommended 
that repeated saliva and serum specimens be submitted in 
addition to CSF and that a postmortem brain specimen be 
actively sought in all suspected rabies cases (18).
Four case-patients who sought treatment at a clinic be-
fore identiﬁ  cation of the outbreak were not offered PEP, 
probably because the risk for rabies infection was not con-
sidered. Our case series includes 1 child in whom rabies de-
veloped despite the administration of seemingly adequate 
PEP. Possible contributing factors to the development of 
rabies in this case include the facial location of the wound, 
possible inadequate wound cleansing, and the fact that all 
of the immunoglobulin could not be inﬁ  ltrated into the 
wound site. The full dose of immunoglobulin should be ad-
ministered on the ﬁ  rst day of PEP and should be inﬁ  ltrated 
into the wound (24,25).
Rabies of the canid biotype has been endemic in C. 
mesomelas in Limpopo Province since the 1950s, with oc-
casional spillover to cattle and domestic dogs. Since 1952, 
several attempts at control have been made, including de-
stroying ≈22,000 dogs in that year, poisoning an estimated 
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3,900 jackals from 1951 through 1956, and vaccinating 
181,414 dogs from 1952 through 1962 (6). Despite these 
efforts, a low incidence of dog rabies was observed in the 
province in the 1960s. Rabies became a serious problem 
again in cattle and jackals in the mid 1970s, likely follow-
ing its reintroduction from Zimbabwe in 1974, and it has 
remained endemic in jackals with sporadic cases occurring 
in domestic dogs (6).
As in a classic situation, this outbreak in humans fol-
lowed an outbreak in domestic dogs of the region. Increas-
ing numbers of human rabies cases in Africa have been 
attributed to increasing numbers in animals, to the mobil-
ity of human and animal populations, and to deteriorat-
ing infrastructure and resources for rabies control (4,26). 
Reasons for the reemergence of canine rabies in Limpopo 
after many years of effective disease control are unclear. 
In Zimbabwe, dog rabies cases increased after 1990, after 
declining vaccination coverage associated with decreased 
resources and diversion of resources (27). Low vaccination 
coverage in domestic dogs in Limpopo over several years 
may have led to an accumulation of susceptible animals, 
which led to the reestablishment of transmission.
The reintroduction of canine rabies into northern Kwa-
Zulu-Natal Province in 1976 followed an inﬂ  ux of refugees 
from Mozambique (6). The possible contribution of in-
creased immigration into Limpopo Province from Zimba-
bwe in recent years is difﬁ  cult to quantify (28). Molecular 
genetic analysis indicates that the virus isolates from both 
humans and dogs in this outbreak were most closely related 
to those from southern Zimbabwe. This ﬁ  nding suggests 
that the outbreak may have extended across the border from 
Zimbabwe.
The number of human rabies cases in Limpopo Prov-
ince decreased after May 2006; no further human cases had 
occurred as of June 30, 2007. This decrease is likely due to 
the introduction of coordinated control measures (includ-
ing aggressive PEP). Although highly effective if adminis-
tered correctly, PEP is much more costly than vaccination 
of domestic dogs (29,30). Unfortunately, dog vaccination 
is difﬁ  cult in many developing countries because of high 
dog turnover rates, shortages of funding and personnel, and 
competing priorities (26,31).
The number of reported human rabies cases, particu-
larly in Africa, greatly underestimates the true effects of the 
disease. Contributing factors include failure to seek treat-
ment at healthcare facilities, failure to make a laboratory 
diagnosis, and failure to report the disease (2,32). Our at-
tempts to conduct active case ﬁ  nding through clinician in-
terviews at hospitals in Vhembe District encountered sev-
eral problems. First, we were unable to review all hospital 
admissions records because of incomplete record keeping. 
We also recognize that at least some infected persons may 
not have visited hospitals and died at home. In addition, 
epidemiologic data were not available for all cases since 
several cases were identiﬁ  ed retrospectively. An increased 
awareness of rabies after interventions for control may 
have contributed to increased case reporting after February 
2006; this situation may have affected apparent trends in 
human case numbers and contributed to the delay in ob-
served decline in dog cases.
This outbreak highlights the fact that rabies is a trans-
boundary disease and can reemerge in areas where suc-
cessful control programs have been active for many years. 
Clinicians should consider rabies in the differential diagno-
sis, especially in cases of fatal encephalitis and submit ap-
propriate specimens for rabies diagnosis. Sustained aware-
ness, together with political and economic commitment to 
animal and human rabies control programs, particularly the 
vaccination of dogs, is essential.
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